Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 9/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 9/20 | 0.53 |
| ▸ | PARP3 | Q9Y6F1 | 9/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.52 |
| ▸ | TNKS | O95271 | 1/20 | 0.49 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2223596 | 0.89 | HDAC4 (0.52) | KDM4EALDH1A1TDP1PARP1PARP2 | |
| SCHEMBL2224982 | 0.88 | HDAC4 (0.57) | KDM4EALDH1A1HDAC4HDAC6HDAC8 | |
| SCHEMBL2228781 | 0.88 | HSD11B1 (0.63) | HDAC4HDAC6HDAC8HDAC2HSD11B1 | |
| SCHEMBL2227593 | 0.85 | HDAC4 (0.48) | HDAC4HDAC6HDAC8HDAC2 | |
| SCHEMBL2226604 | 0.84 | SLC6A7 (0.62) | KDM4EALDH1A1HDAC4HDAC6HDAC8 | |
| SCHEMBL2227491 | 0.83 | HDAC4 (0.46) | HDAC4HDAC6HDAC8HDAC2 | |
| SCHEMBL2227789 | 0.82 | HDAC4 (0.62) | KDM4EHDAC4HDAC6HDAC8HDAC2 | |
| SCHEMBL2223611 | 0.82 | HDAC4 (0.59) | KDM4EALDH1A1HDAC4HDAC6HDAC8 | |
| SCHEMBL2226665 | 0.81 | HDAC4 (0.52) | ALDH1A1PARP1HDAC4HDAC6HDAC8 | |
| SCHEMBL2227709 | 0.81 | STAT3 (0.51) | KDM4EHDAC4HDAC6HDAC8HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | claimed |
| WO-2013009827-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | claimed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | claimed |
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| WO-2013009827-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | disclosed |
| EP-2523664-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| WO-2011088192-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088192-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289495-A1 | COMPOUNDS AND METHODS | XDH, CCNY, TOP2B | KDM4E 2352/4885ALDH1A1 1319/4885TDP1 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.